ReviewNeurobiology of aging2011
Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants.
Review in Neurobiology of aging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Assessment of Plasma Amyloid-β42/40 and Cognitive Decline Among Community-Dwelling Older Adults.JAMA network open · 2020Trial
- Blood-based biomarkers in mild behavioral impairment: an updated overview.Frontiers in neurology · 2025Review
- Comparing Symmetric Dimethylarginine and Amyloid-β42 as Predictors of Alzheimer's Disease Development.Journal of Alzheimer's disease reports · 2023Article
- Using CNN Saliency Maps and EEG Modulation Spectra for Improved and More Interpretable Machine Learning-Based Alzheimer's Disease Diagnosis.Computational intelligence and neuroscience · 2023Article
- Blood-based biomarkers in Alzheimer's disease: a mini-review.Metabolic brain disease · 2023Review
- Mechanistic considerations and biomarkers level in nickel-induced neurodegenerative diseases: An updated systematic review.IBRO neuroscience reports · 2022Review
- A transcriptome-wide association study identifies novel blood-based gene biomarker candidates for Alzheimer's disease risk.Human molecular genetics · 2021Article
- Correlation between Alzheimer's disease and type 2 diabetes using non-negative matrix factorization.Scientific reports · 2021Article
- Plasma Biomarkers of Alzheimer's Disease in African Americans.Journal of Alzheimer's disease : JAD · 2021Article
- Multimodal Prediction of Alzheimer's Disease Severity Level Based on Resting-State EEG and Structural MRI.Frontiers in human neuroscience · 2021Article
- Examination of BDNF Treatment on BACE1 Activity and Acute Exercise on Brain BDNF Signaling.Frontiers in cellular neuroscience · 2021Article
- Dynamic Blood Concentrations of AβFrontiers in cell and developmental biology · 2020Article
- Application of Electrochemical Aptasensors toward Clinical Diagnostics, Food, and Environmental Monitoring: Review.Sensors (Basel, Switzerland) · 2019Review
- Spatial correlations exploitation based on nonlocal voxel-wise GWAS for biomarker detection of AD.NeuroImage. Clinical · 2019Article
- A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer's pathology and cognitive impairment.Alzheimer's & dementia (Amsterdam, Netherlands) · 2018Article
- The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer's disease.Alzheimer's research & therapy · 2017Article
- Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017Article
- Plasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer's disease.Scientific reports · 2017Article
- The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII.Journal of thrombosis and haemostasis : JTH · 2016Article
- Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Identifying a biomarker for Alzheimer's disease that can be obtained from a blood sample has been a goal of researchers for many years. Over the past few years a number of investigators have studied several plasma biomarkers but most frequently plasma amyloid beta (Aβ)40 and Aβ42 while others have explored the use of genetic variants as biomarkers for diagnosis or risk. This review considers the cross-sectional and longitudinal data regarding plasma Aβ40 and Aβ42 as diagnostic biomarkers as well as risk biomarkers. Review of recent genome-wide association studies indicates as many as 10 genetic variants have been associated with susceptibility to Alzheimer's disease (AD). Further analysis suggests that these factors have modest effects on risk and are thus not helpful, as yet, in the diagnosis of disease. Until the function of these genes is understood, their role in risk and diagnosis will remain uncertain. Thus, there are several types of peripheral biomarkers under investigation, but more work is required before they can be deemed clinically useful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.